Microarray Screening for IgE-FcεR1 Binding Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for alleviating allergy, atopy, and skin itching are limited by high toxicity and side effects, and existing screening methods are expensive and inefficient for analyzing multiple samples.
Innovation Solution
A method involving a linker material-coated substrate treated with capture protein, biotin-conjugated IgE, and fluorescently labeled streptavidin is used to screen functional materials that interfere with the binding between IgE and its receptor FcεR1, allowing for direct analysis of protein interaction and potential allergenic response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional ELISA plate-based assay methods are used to screen functional materials, then the analysis can be performed with established protocols, but the cost is high and the throughput is low
Solution Approach 1:
The invention segments the ELISA process into a microarray format where multiple samples and reagents are arranged in spatial arrays on a single substrate. This allows parallel processing of multiple samples simultaneously, dramatically increasing throughput while maintaining the specificity and accuracy of binding interaction analysis through controlled spatial positioning of capture proteins and test materials
Solution Approach 2:
The invention merges multiple ELISA assays into a single microarray platform, combining sample application, reagent incubation, washing, and detection steps into one integrated system. This consolidation enables high-throughput screening of multiple functional materials against IgE-FcεR1 binding while reducing per-sample cost through shared reagents and processing infrastructure
2Reliability
If conventional screening methods are used, then the procedures are well-established, but the cost is high and time-consuming
Solution Approach 1:
The invention employs preliminary action by pre-coating the microarray substrate with capture proteins (such as FcεR1) before sample application. This pre-preparation allows samples to be directly applied to ready-to-use arrays, eliminating time-consuming setup steps and enabling rapid sequential processing of multiple samples while maintaining reliable binding interaction detection
Solution Approach 2:
The invention changes the physical and temporal parameters of the screening process by reducing incubation times, optimizing reagent concentrations, and implementing rapid washing protocols specific to microarray formats. These parameter optimizations maintain the validity and reliability of binding assays while significantly reducing the total screening time compared to conventional ELISA methods
3Object-affected harmful factors
If steroidal agents and immunosuppressants are used for atopic dermatitis treatment, then the therapeutic effect is achieved, but side effects such as abnormal immune function occur with long-term use
Solution Approach 1:
The invention uses an intermediary approach by identifying functional materials that specifically block the IgE-FcεR1 binding interaction without suppressing overall immune function. These materials act as selective mediators that prevent allergic reactions by interfering with the specific pathogenic pathway while leaving other immune functions intact, thereby achieving therapeutic effect without the broad immunosuppression and side effects associated with conventional steroidal and immunosuppressant treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables efficient and cost-effective analysis of multiple samples, confirming the binding interaction between IgE and FcεR1, and identifying materials that inhibit allergic reactions, with results obtained within 3 to 12 hours and at a fraction of the cost of traditional ELISA methods.
Implementation Method 1
treating a linker material-coated substrate with a capture protein
Implementation Method 2
treating the capture protein-treated substrate with biotin-conjugated IgE
Implementation Method 3
treating the biotin-conjugated IgE-treated substrate with fluorescently labeled streptavidin
Implementation Method 4
fluorescently labeled streptavidin
Data Source
AI summary
A method for screening a functional material according to the present invention comprises steps of: treating a linker material-coated substrate with a capture protein; treating the capture protein-treated substrate with a functional material candidate; treating the functional material candidate-treated substrate with biotin-conjugated IgE; and treating the biotin-bound IgE-treated substrate with fluorescently labeled streptavidin.